Oral domperidone versus placebo for enhancing exclusive breastfeeding among post-lower segment cesarean section mothers – a double-blind randomized controlled trial

Figures & data

Figure 1. Consolidated Standards Of Reporting Trials (CONSORT) Diagram.

Table 1. Baseline characteristics and maternal clinical profile.

	Group A (Domperidone arm) n = 183		Group B (Placebo arm) n = 183
	Mean ± SD	C.I	Mean ± SD	C.I	p value
Maternal Age	26.29 ± 4.48	25.64–26.94	26.75 ± 5.04	26.01-27.49	.358
Pre-pregnant BMI	25.14 ± 3.67	24.61–25.68	25.82 ± 3.79	25.27-26.37	.081
Birth weight (kg)	2.84 ± 0.54	2.76–2.92	2.85 ± 0.53	2.77-2.92	.992
Gestational age (weeks)	37.95 ± 1.53	37.73–38.17	38.11 ± 1.52	37.89-38.33	.339
	Frequency	Proportion %	Frequency	Proportion %
Gestational diabetes mellitus	23	12.57	19	10.38	.512
Gestational hypertension	17	9.29	15	8.20	.711
Preeclampsia	11	6.01	9	4.92	.646
Eclampsia	1	0.55	1	0.55	.000
Hypothyroid	19	10.38	22	12.02	.619
Chronic diabetes mellitus	4	2.19	6	3.28	.521
Chronic hypertension	2	1.09	3	1.64	.652

Table 2. Exclusive breastfeeding rates.

	Group A Domperidone (n = 183)		Group B Placebo (n = 183)
	Frequency	Proportion %	Frequency	Proportion %	p value*
7 days	176	96.17	157	85.79	.001
3 months	141	77.05	131	71.58	.232
6 months	119	65.03	107	58.47	.197

Table 3. Weight gain of infants.

	Group A (Domperidone arm)		Group B (Placebo arm)
[9]	Mean ± SD	C.I	Mean ± SD	C.I	p value*
6 weeks	0.95 ± 0.36	0.9–1.01	0.9 ± 0.34	0.85–0.95	.119
10weeks	2.05 ± 0.59	1.97–2.14	1.97 ± 0.53	1.89–2.04	.144
14 weeks	3.4 ± 0.77	3.29–3.51	3.27 + 0.59	3.18–3.36	.071
9 months	5.2 ± 1.03	5.05–5.35	5.05 ± 1.03	4.9–5.2	.167